Academic Journal
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir
| Title: | Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir |
|---|---|
| Authors: | Ankrom, Wendy, Sanchez, Rosa I., Yee, Ka Lai, Fan, Li, Mitra, Pranab, Wolford, Dennis, Triantafyllou, Ilias, Sterling, Laura M., Stoch, S. Aubrey, Iwamoto, Marian, Khalilieh, Sauzanne |
| Contributors: | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA |
| Source: | Antimicrobial Agents and Chemotherapy ; volume 63, issue 5 ; ISSN 0066-4804 1098-6596 |
| Publisher Information: | American Society for Microbiology |
| Publication Year: | 2019 |
| Description: | Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Due to the high prevalence of HIV-1 and hepatitis C virus (HCV) coinfection and coadministration of HIV-1 and HCV treatment, potential drug-drug interactions (DDIs) between doravirine and two HCV treatments were investigated in two phase 1 drug interaction trials in healthy participants. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| DOI: | 10.1128/aac.02491-18 |
| DOI: | 10.1128/AAC.02491-18 |
| Availability: | https://doi.org/10.1128/aac.02491-18 https://journals.asm.org/doi/pdf/10.1128/AAC.02491-18 |
| Rights: | https://journals.asm.org/non-commercial-tdm-license |
| Accession Number: | edsbas.67DBC838 |
| Database: | BASE |
| DOI: | 10.1128/aac.02491-18 |
|---|